Clinical Trials · NCT05567796

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Name: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Semaglutide Cagrilintide

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: Novo Nordisk A/S
Enrollment: 3,400
Start date: Nov 2022
Locations: 256 sites, 23 countries
Primary endpoint: CagriSema versus placebo: Relative change in body weight

View Semaglutide compound reference